

# BÖLÜM 25



## STATİN DIŐI DİSLİPİDEMİ TEDAVİSİ

İdris YAKUT<sup>1</sup>

### GİRİŐ

Statinler, kardiyovasküler hastalıkların primer ve sekonder korunmasında ve düşük yoğunluklu lipoprotein kolesterol (LDL-C) düzeyinin düşürülmesinde ana tedavi düzlemini oluşturmaktadır. Statinler ile yeterli LDL-C yanıtı sağlanamaması, statin intoleransı ve statinlerin kullanılmayacağı gebelik gibi durumlarda statin dışı dislipidemi tedavisi önem kazanmaktadır. Ayrıca hipertrigliserideminin kardiyovasküler ve pankreatit gibi sonlanımlarından dolayı statin dışı tedavilere ihtiyaca neden olmaktadır. Statin ve statin dışı lipit düşürücü ajan kombinasyonlarının LDL-C düşürücü güçleri ve etkileri tablo 1'de gösterilmiştir.<sup>1</sup> Bu bölümde dislipidemi tedavisinde kullanılan statin dışı ajanlar ele alınacaktır.

Tablo 1: Lipit düşürücü ilaçların etki gücü

Tedavi	Ortalama LDL-C düşüşü
Orta yoğunluklu statin(OY)	~%30
Yüksek yoğunluklu statin(YY)	~%50
YY statin + Ezetimib	~%65
PCSK9 inh	~%60
PCSK9 inh + YY statin	~%75
PCSK9 inh + YY statin + Ezetimib	~%85

<sup>1</sup> Uzm. Dr. Ankara Gazi Mustafa Kemal Mesleki ve Çevresel Hastalıklar Hastanesi, Kardiyoloji Bölümü  
idrislive@windowslive.com

## KAYNAKLAR

1. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. *Atherosclerosis*. 2019;290:140-205.
2. Brunton LL, Chabner B, Knollmann BC. Goodman & Gilman's the pharmacological basis of the-rapeutics: McGraw-Hill Education New York; 2018.
3. Mazidi M, Rezaie P, Karimi E, Kengne AP. The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: a systematic review and meta-analysis of randomized controlled trials. *International journal of cardiology*. 2017;227:850-7.
4. Katzung BG. Basic and clinical pharmacology 14th edition: McGraw Hill Professional; 2017.
5. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AA-CVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. *Journal of the American College of Cardiology*. 2019;73(24):e285-e350.
6. Members TF, Guidelines ECFP. 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. *Atherosclerosis*. 2019;290:140-205.
7. Harvey RA, Clark M, Finkel R, Rey J, Whalen K. Lippincott's illustrated reviews: Pharmacology: Philadelphia; 2012.
8. D'Andrea E, Hey SP, Ramirez CL, Kesselheim AS. Assessment of the role of niacin in managing cardiovascular disease outcomes: a systematic review and meta-analysis. *JAMA network open*. 2019;2(4):e192224-e.
9. Kim NH, Kim SG. Fibrates revisited: potential role in cardiovascular risk reduction. *Diabetes & metabolism journal*. 2020;44(2):213-21.
10. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. *Pharmacology & therapeutics*. 2010;126(3):314-45.
11. Fruchart JC, Hermans MP, Fruchart-Najib J, Kodama T. Selective Peroxisome Proliferator-Activa-ted Receptor Alpha Modulators (SPPARMo) in the Metabolic Syndrome: Is Pemafibrate Light at the End of the Tunnel? *Current atherosclerosis reports*. 2021;23(1):3.
12. Sahebkar A, Simental-Mendiá LE, Watts GF, Serban M-C, Banach M. Comparison of the effects of fibrates versus statins on plasma lipoprotein (a) concentrations: a systematic review and me-ta-analysis of head-to-head randomized controlled trials. *BMC medicine*. 2017;15(1):1-14.
13. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AA-CVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;139(25):e1082-e143.
14. Okopień B, Bułdak Ł, Bóldys A. Benefits and risks of the treatment with fibrates—a compre-hensive summary. *Expert Review of Clinical Pharmacology*. 2018;11(11):1099-112.
15. Ascah KJ, Rock GA, Wells PS. Interaction between fenofibrate and warfarin. *The Annals of phar-macotherapy*. 1998;32(7-8):765-8.
16. Gilman MTA. Goodman Gilman's The Pharmacological Basis Of Therapeutics 13th Edition. 2011.
17. Pradhan A, Bhandari M, Sethi R. Ezetimibe and improving cardiovascular outcomes: current evi-dence and perspectives. *Cardiology Research and Practice*. 2020;2020.
18. Carabello BA. The SEAS trial. *Current cardiology reports*. 2010;12(2):122-4.
19. Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Lokhnygina Y, et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IM-PROVE-IT trial. *Journal of the American College of Cardiology*. 2016;67(4):353-61.
20. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, et al. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database of Sys-tematic Reviews*. 2018(11).
21. Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, et al. ASCEND Study Colla-borative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. *The New England journal of medicine*. 2018;379(16):1529-39.

22. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Effects of icosapent ethyl on total ischemic events: from REDUCE-IT. *Journal of the American College of Cardiology*. 2019;73(22):2791-802.
23. Whalen K. Lippincott® Illustrated Reviews: Pharmacology; Wolters kluwer india Pvt Ltd; 2018.
24. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *New England Journal of Medicine*. 2015;372(16):1489-99.
25. Thedrez A, Blom DJ, Ramin-Mangata S, Blanchard V, Croyal M, Chemello K, et al. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor) Implications for the Efficacy of Evolocumab. *Arteriosclerosis, thrombosis, and vascular biology*. 2018;38(3):592-8.
26. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. *New England Journal of Medicine*. 2017;376(18):1713-22.
27. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. *New England Journal of Medicine*. 2018;379(22):2097-107.
28. Mannarino MR, Sahebkar A, Bianconi V, Serban M-C, Banach M, Pirro M. PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results? *Journal of Clinical Lipidology*. 2018;12(5):1123-32.
29. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology*. 2019;73(24):e285-e350.
30. Ridker PM, Tardif J-C, Amarenco P, Duggan W, Glynn RJ, Jukema JW, et al. Lipid-reduction variability and antidrug-antibody formation with bococizumab. *New England Journal of Medicine*. 2017;376(16):1517-26.
31. D'Erasmus L, Bini S, Arca M. Rare treatments for rare dyslipidemias: new perspectives in the treatment of homozygous familial hypercholesterolemia (HoFH) and familial chylomicronemia syndrome (FCS). *Current atherosclerosis reports*. 2021;23(11):1-12.
32. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolemia: a single-arm, open-label, phase 3 study. *The Lancet*. 2013;381(9860):40-6.
33. Flower R, Henderson G, Loke Y, MacEwan D. Rang & Dale's Pharmacology E-Book. Elsevier Health Sciences: Amsterdam, The Netherlands; 2018.
34. Rader DJ, Kastelein JJ. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. *Circulation*. 2014;129(9):1022-32.
35. Ballantyne CM, Bays H, Catapano AL, Goldberg A, Ray KK, Saseen JJ. Role of bempedoic acid in clinical practice. *Cardiovascular Drugs and Therapy*. 2021;35(4):853-64.
36. Hardy J, Niman S, Pereira E, Lewis T, Reid J, Choksi R, et al. A critical review of the efficacy and safety of inclisiran. *American Journal of Cardiovascular Drugs*. 2021;21(6):629-42.
37. Kosmas CE, Muñoz Estrella A, Sourlas A, Silverio D, Hilario E, Montan PD, et al. Inclisiran: a new promising agent in the management of hypercholesterolemia. *Diseases*. 2018;6(3):63.